In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device/Diagnostics Quarterly Deal Statistics, Q2 2013

A look at financing, M&A, and alliance activity, April–June 2013

Executive Summary

Similar to Q1’s deal dollars and volume, device companies raised $1.06 billion through 45 transactions; Bayer HealthCare’s $1 billion purchase of Conceptus was the only device M&A in Q2 to exceed the billion-dollar mark. Diagnostics players raised a total of $2.9 billion during the second quarter, a huge increase over Q1 due to Thermo Fisher Scientific’s $2.46 billion follow-on offering to support its $15.2 billion April acquisition of Life Technology, another Q2 outlier in the M&A category.

Advertisement

Related Content

FDA’s Augment Letter May Force Wright to Rewrite Turnaround Story
MicroPort’s Wright Bid Creates New Ortho Player
Bard EP Deal Latest In Boston Scientific’s M&A Revival, Bolsters CRM Business
Epizyme Execs On Company’s IPO, Clinical Progress And Diagnostic Strategy
Extremities, Emerging Markets Continue To Top M&A Ortho Interest
BTG Makes Two Buys To Build Interventional Medicine Business
Life Technologies Extends Thermo Fisher’s Reach Into Clinical Practice
Bayer Buys Essure Contraceptive-Maker Conceptus For $1.1 Billion

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel